Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:AMT NYSE:FPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.17-5.3%$5.65$2.90▼$11.16$340.26M0.473.36 million shs1.70 million shsAMTAmerican Tower$219.14-0.8%$216.48$172.51▼$243.56$102.61B0.822.50 million shs245,805 shsFPHFive Point$6.00-0.7%$5.55$2.88▼$6.71$892.26M1.53293,656 shs34,559 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-7.17%-7.56%-34.72%-0.23%-41.18%AMTAmerican Tower-0.22%-0.28%+3.08%+3.69%+12.38%FPHFive Point+4.33%+4.69%+7.30%+26.65%+105.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.355 of 5 stars3.41.00.00.03.11.70.6AMTAmerican Tower4.0206 of 5 stars2.63.01.73.14.21.70.0FPHFive Point1.3387 of 5 stars0.04.00.00.00.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.75Moderate Buy$18.20336.66% UpsideAMTAmerican Tower 3.11Buy$240.889.92% UpsideFPHFive Point 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest FPH, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/8/2025AMTAmerican TowerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$250.00 ➝ $260.006/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/19/2025AMTAmerican TowerBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$255.005/1/2025AMTAmerican TowerRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$240.00 ➝ $250.004/30/2025AMTAmerican TowerWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$230.00 ➝ $240.004/30/2025AMTAmerican TowerScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$234.00 ➝ $248.004/30/2025AMTAmerican TowerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$248.00 ➝ $260.004/30/2025AMTAmerican TowerRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$231.00 ➝ $251.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,903.32N/AN/A$1.74 per share2.40AMTAmerican Tower$10.13B10.13$11.44 per share19.16$20.64 per share10.62FPHFive Point$237.93M3.75$0.61 per share9.80$14.50 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)AMTAmerican Tower$2.26B$3.8956.3421.911.6517.34%30.20%4.82%7/29/2025 (Estimated)FPHFive Point$68.30M$1.254.80∞N/A37.01%4.23%2.95%7/17/2025 (Estimated)Latest FPH, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/AN/AN/A7/29/2025Q2 2025AMTAmerican Tower$2.59N/AN/AN/A$2.58 billionN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/29/2025Q1 2025AMTAmerican Tower$2.41$2.75+$0.34$2.75$2.54 billion$2.56 billion4/24/2025Q1 2025FPHFive PointN/A$0.32N/A$0.32N/A$13.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.10%N/A174.81%1 YearsFPHFive PointN/AN/AN/AN/AN/ALatest FPH, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/15/2025AMTAmerican Towerquarterly$1.703.21%6/13/20256/13/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85AMTAmerican Tower3.430.810.81FPHFive PointN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%FPHFive Point38.09%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.17%FPHFive Point21.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableAMTAmerican Tower4,691468.14 million467.34 millionOptionableFPHFive Point100148.71 million116.75 millionNot OptionableFPH, ADR, AMT, and ALT HeadlinesRecent News About These CompaniesFive Point (NYSE:FPH) Trading Up 4.3% - Time to Buy?July 10 at 12:56 AM | marketbeat.comFPH - Five Point Holdings LLC A Key Metrics | MorningstarJune 27, 2025 | morningstar.comMFive Point Holdings, LLC (FPH) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comFive Point to acquire controlling interest in Hearthstone VentureJune 21, 2025 | finance.yahoo.comFive Point Holdings to Buy Homebuilding InvestorJune 20, 2025 | ocbj.comOFive Point Holdings, LLC to Acquire Controlling Interest in New Landbank Venture With Hearthstone, Inc.June 20, 2025 | finance.yahoo.comFive Point to acquire controlling interest in business, operations of HearthstoneJune 20, 2025 | msn.comFive Point launches $1B PowerBridge to build massive data centers in West TexasMay 24, 2025 | msn.comShould You Be Adding Five Point Holdings (NYSE:FPH) To Your Watchlist Today?May 18, 2025 | uk.finance.yahoo.comFive Point Infrastructure forms PowerBridge with $1bn equity commitmentMay 16, 2025 | pehub.comFive Point Holdings, LLC’s (FPH) Strong Year-End Sales Enhance Financial Stability for Future DevelopmentsMay 9, 2025 | insidermonkey.comFive Point Holdings, LLC (FPH): A Bull Case TheoryMay 7, 2025 | insidermonkey.comHere are O’Keefe Stevens Advisory’s Updates on Five Point Holdings, LLC (FPH)May 2, 2025 | insidermonkey.comWhy Five Point Holdings LLC (FPH) Is Surging In 2025April 30, 2025 | msn.comWhy Five Point Holdings, LLC’s (FPH) Stock Is Down 5.46%April 29, 2025 | aaii.comAFive Point Holdings, LLC (NYSE:FPH) Q1 2025 Earnings Call TranscriptApril 27, 2025 | insidermonkey.comQ1 2025 Five Point Holdings LLC Earnings CallApril 27, 2025 | finance.yahoo.comFivePoint reveals timetable for key work to begin at Candlestick PointApril 26, 2025 | bizjournals.comFive Point Hldgs Stock Price, Quotes and Forecasts | NYSE:FPH | BenzingaApril 24, 2025 | benzinga.comFive point holdings targets $200M net income for 2025 amid strategic growth initiativesApril 24, 2025 | msn.comFive Point Holdings, LLC (FPH) Q1 2025 Earnings Call TranscriptApril 24, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseInsiders Chase Income and Stability in American Tower—Here’s WhyBy Gabriel Osorio-Mazilli | June 25, 2025View Insiders Chase Income and Stability in American Tower—Here’s WhyFPH, ADR, AMT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$4.17 -0.23 (-5.27%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American Tower NYSE:AMT$219.14 -1.87 (-0.85%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.Five Point NYSE:FPH$6.00 -0.05 (-0.75%) As of 11:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Five Point Holdings, LLC, through its subsidiary, Five Point Operating Company, LP, owns and develops mixed-use and planned communities in Orange County, Los Angeles County, and San Francisco County. The company operates in four segments: Valencia, San Francisco, Great Park, and Commercial. It sells residential and commercial land sites to homebuilders, commercial developers, and commercial buyers; operates and owns a commercial office, research and development, medical campus, and other properties; and provides development and property management services. The company was formerly known as Newhall Holding Company, LLC and changed its name to Five Point Holdings, LLC in May 2016. Five Point Holdings, LLC was incorporated in 2009 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
